Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Adoptive Cell Therapy
Treatment CD8α:MyD88-engineered T cells
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature Th2
Official Symbol NA
Mode of action PROT_D_DOWN
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description CCL2, which is involved in monocyte recruitment, Th2 polarization, and tumor progression, was decreased nearly three-fold in the tumors of CD8:MyD88 T cell–treated mice. Likewise, IL-5, which has been associated with Th2 responses and pro-tumor effects, was decreased following treatment with CD8:MyD88 T cells.
PMID 29055013
Title A Synthetic CD8α:MyD88 Coreceptor Enhances CD8 + T-cell Responses to Weakly Immunogenic and Lowly Expressed Tumor Antigens